Gabriel Contreras, MD MPH

I earned my medical degree in 1987 from the Autonomous University of Guadalajara in Mexico. I trained in Internal medicine, nephrology, hypertension, critical care, and earned a degree as Master in Public Health between 1989 and 2003. Subsequently, I joined the School of Medicine at the University of Miami. During my time as faculty in the Department of Medicine, I have been involved in the development and establishment of a successful clinical research program in the Division of Nephrology with the accrual of 21 research grants, 68 publications in peer review Journals, and 5 Chapters publications in textbooks. In the 18 years of my academic career, I have kept research funding from different sources such as the Kidney Foundation of South Florida, the Veterans Affairs Cooperative Study Program, the National Institute of Health (NIH) and the Pharmaceutical Industry. I have an ongoing commitment to improving kidney disease outcomes among racial and ethnic minorities throughout the clinical research program at the University of Miami Miller School of medicine. This is evidenced in part by funding for the University of Miami as a key site in the African American Study of Kidney Disease and Hypertension (AASK) trial-cohort, a multi-center, NIH-funded study of risk factors for the prevention and treatment of kidney disease progression among African Americans. I have ongoing funding also as a site Principal Investigator at University of Miami for the Systolic Blood Pressure Intervention Trial (SPRINT) which is sponsored by the National Institutes of Health (NHLBI, NIDDK, NIA and NINDS) throughout Wake Forest University. This is a multicenter clinical trial study exploring the effect of intensive systolic blood pressure control on the risk for cardiovascular and renal diseases. Along with that important work, I have been also engaged in a number of internationally recognized clinical trials of novel treatments for lupus nephritis in racially and ethnically diverse populations. I have ongoing funding as a site Principal Investigator at University of Miami for Randomized, Double-Blind, Controlled, Phase II Multicenter Trial of CTLA4Ig (Abatacept) Plus Cyclophosphamide vs. Cyclophosphamide Alone in the Treatment of Lupus Nephritis. Study funded by National Institutes of Health – NIAID through The University of California. These trials are considered milestone studies that are improving the care of patients.